221 related articles for article (PubMed ID: 15599890)
1. Inflammation and oxidative stress in ESRD--the role of myeloperoxidase.
Maruyama Y; Lindholm B; Stenvinkel P
J Nephrol; 2004; 17 Suppl 8():S72-6. PubMed ID: 15599890
[TBL] [Abstract][Full Text] [Related]
2. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?
Himmelfarb J
Semin Dial; 2004; 17(6):449-54. PubMed ID: 15660575
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease.
Stenvinkel P; Lindholm B; Heimbürger O
Semin Dial; 2004; 17(6):505-15. PubMed ID: 15660582
[TBL] [Abstract][Full Text] [Related]
4. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy.
Stenvinkel P; Diczfalusy U; Lindholm B; Heimbürger O
Nephrol Dial Transplant; 2004 Apr; 19(4):972-6. PubMed ID: 15031358
[TBL] [Abstract][Full Text] [Related]
6. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy.
Himmelfarb J
Semin Dial; 2009; 22(6):636-43. PubMed ID: 20017834
[TBL] [Abstract][Full Text] [Related]
7. [Chronic inflammation and cardiovascular risk in hemodialysis].
Pertosa G; Simone S; Soccio M; Marrone D; Grandaliano G
G Ital Nefrol; 2003; 20(6):631-40. PubMed ID: 14732917
[TBL] [Abstract][Full Text] [Related]
8. [Malnutrition -- inflammation -- atherosclerosis (MIA syndrome) in patients with renal failure].
Pawlaczyk K; Oko A; Lindholm B; Czekalski S
Pol Merkur Lekarski; 2003 Oct; 15(88):334-41; discussion 341-3. PubMed ID: 14974361
[TBL] [Abstract][Full Text] [Related]
9. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease.
Stenvinkel P
J Ren Nutr; 2003 Apr; 13(2):144-8. PubMed ID: 12671839
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol in end-stage renal disease: the good, the bad or the ugly?
Diepeveen SH; Wetzels JF; Bilo HJ; van Tits LJ; Stalenhoef AF
Neth J Med; 2008 Feb; 66(2):53-61. PubMed ID: 18292607
[TBL] [Abstract][Full Text] [Related]
11. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.
Stenvinkel P; Rodríguez-Ayala E; Massy ZA; Qureshi AR; Barany P; Fellström B; Heimburger O; Lindholm B; Alvestrand A
Clin J Am Soc Nephrol; 2006 Mar; 1(2):281-7. PubMed ID: 17699218
[TBL] [Abstract][Full Text] [Related]
12. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
Martola L; Elinder CG; Stenvinkel P
Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
[TBL] [Abstract][Full Text] [Related]
13. Inflammation in end-stage renal disease: the hidden enemy.
Stenvinkel P
Nephrology (Carlton); 2006 Feb; 11(1):36-41. PubMed ID: 16509930
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure.
La Rocca G; Di Stefano A; Eleuteri E; Anzalone R; Magno F; Corrao S; Loria T; Martorana A; Di Gangi C; Colombo M; Sansone F; Patanè F; Farina F; Rinaldi M; Cappello F; Giannuzzi P; Zummo G
Basic Res Cardiol; 2009 May; 104(3):307-20. PubMed ID: 19030913
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress in chronic renal failure as a cardiovascular risk factor.
Siems W; Quast S; Carluccio F; Wiswedel I; Hirsch D; Augustin W; Hampi H; Riehle M; Sommerburg O
Clin Nephrol; 2002 Jul; 58 Suppl 1():S12-9. PubMed ID: 12227720
[TBL] [Abstract][Full Text] [Related]
16. Functional polymorphism of the myeloperoxidase gene in hypertensive nephrosclerosis dialysis patients.
Doi K; Noiri E; Maeda R; Nakao A; Kobayashi S; Tokunaga K; Fujita T
Hypertens Res; 2007 Dec; 30(12):1193-8. PubMed ID: 18344624
[TBL] [Abstract][Full Text] [Related]
17. Assessment of inflammation and nutrition in patients with end-stage renal disease.
Don BR; Kaysen GA
J Nephrol; 2000; 13(4):249-59. PubMed ID: 10946803
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure.
Cottone S; Lorito MC; Riccobene R; Nardi E; Mulè G; Buscemi S; Geraci C; Guarneri M; Arsena R; Cerasola G
J Nephrol; 2008; 21(2):175-9. PubMed ID: 18446711
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality.
Matsubara K; Suliman ME; Qureshi AR; Axelsson J; Martola L; Heimbürger O; Barany P; Stenvinkel P; Lindholm B
Blood Purif; 2008; 26(3):284-90. PubMed ID: 18421213
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oxidative damage in Malaysian end-stage renal disease patients with or without non-insulin-dependent diabetes mellitus.
Kuppusamy UR; Indran M; Ahmad T; Wong SW; Tan SY; Mahmood AA
Clin Chim Acta; 2005 Jan; 351(1-2):197-201. PubMed ID: 15563890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
